Your browser doesn't support javascript.
loading
Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.
Pirker, Christine; Bilecz, Agnes; Grusch, Michael; Mohr, Thomas; Heidenreich, Barbara; Laszlo, Viktoria; Stockhammer, Paul; Lötsch-Gojo, Daniela; Gojo, Johannes; Gabler, Lisa; Spiegl-Kreinecker, Sabine; Dome, Balazs; Steindl, Ariane; Klikovits, Thomas; Hoda, Mir Alireza; Jakopovic, Marko; Samarzija, Miroslav; Mohorcic, Katja; Kern, Izidor; Kiesel, Barbara; Brcic, Luka; Oberndorfer, Felicitas; Müllauer, Leonhard; Klepetko, Walter; Schmidt, Wolfgang M; Kumar, Rajiv; Hegedus, Balazs; Berger, Walter.
Afiliación
  • Pirker C; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Bilecz A; 2nd Institute of Pathology, Semmelweis University, Budapest, Hungary.
  • Grusch M; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Mohr T; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Heidenreich B; Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Laszlo V; Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University Vienna, Austria.
  • Stockhammer P; Department of Tumor Biology, National Koranyi Institute of Pulmonology, Semmelweis University, Budapest, Hungary.
  • Lötsch-Gojo D; Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University Vienna, Austria.
  • Gojo J; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Gabler L; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Spiegl-Kreinecker S; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Dome B; Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Steindl A; Department of Neurosurgery, Neuromed Campus, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
  • Klikovits T; Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University Vienna, Austria.
  • Hoda MA; Department of Tumor Biology, National Koranyi Institute of Pulmonology, Semmelweis University, Budapest, Hungary.
  • Jakopovic M; Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary.
  • Samarzija M; Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University Vienna, Austria.
  • Mohorcic K; Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University Vienna, Austria.
  • Kern I; Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University Vienna, Austria.
  • Kiesel B; Department for Respiratory Diseases Jordanovac, University Hospital Center, University of Zagreb, Zagreb, Croatia.
  • Brcic L; Department for Respiratory Diseases Jordanovac, University Hospital Center, University of Zagreb, Zagreb, Croatia.
  • Oberndorfer F; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Müllauer L; University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
  • Klepetko W; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
  • Schmidt WM; Medical University of Graz, Diagnostic and Research Institute of Pathology, Graz, Austria.
  • Kumar R; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.
  • Hegedus B; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.
  • Berger W; Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University Vienna, Austria.
Clin Cancer Res ; 26(14): 3819-3830, 2020 07 15.
Article en En | MEDLINE | ID: mdl-32317288
PURPOSE: Human malignant pleural mesothelioma (MPM) is characterized by dismal prognosis. Consequently, dissection of molecular mechanisms driving malignancy is of key importance. Here we investigate whether activating mutations in the telomerase reverse transcriptase (TERT) gene promoter are present in MPM and associated with disease progression, cell immortalization, and genomic alteration patterns. EXPERIMENTAL DESIGN: TERT promoters were sequenced in 182 MPM samples and compared with clinicopathologic characteristics. Surgical specimens from 45 patients with MPM were tested for in vitro immortalization. The respective MPM cell models (N = 22) were analyzed by array comparative genomic hybridization, gene expression profiling, exome sequencing as well as TRAP, telomere length, and luciferase promoter assays. RESULTS: TERT promoter mutations were detected in 19 of 182 (10.4%) MPM cases and significantly associated with advanced disease and nonepithelioid histology. Mutations independently predicted shorter overall survival in both histologic MPM subtypes. Moreover, 9 of 9 (100%) mutated but only 13 of 36 (36.1%) wild-type samples formed immortalized cell lines. TERT promoter mutations were associated with enforced promoter activity and TERT mRNA expression, while neither telomerase activity nor telomere lengths were significantly altered. TERT promoter-mutated MPM cases exhibited distinctly reduced chromosomal alterations and specific mutation patterns. While BAP1 mutations/deletions were exclusive with TERT promoter mutations, homozygous deletions at the RBFOX1 and the GSTT1 loci were clearly enriched in mutated cases. CONCLUSIONS: TERT promoter mutations independently predict a dismal course of disease in human MPM. The altered genomic aberration pattern indicates that TERT promoter mutations identify a novel, highly aggressive MPM subtype presumably based on a specific malignant transformation process.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pleurales / Biomarcadores de Tumor / Telomerasa / Mesotelioma Maligno Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pleurales / Biomarcadores de Tumor / Telomerasa / Mesotelioma Maligno Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Estados Unidos